For Healthcare Professionals

Brightline-2 (1403.11): A Phase 2a/2b, open-label, single-arm, multicenter trial of brigimadlin (MDM2-p53 antagonist)^a for the treatment of patients with locally advanced/metastatic, MDM2-amplified, TP53 wt BTC, PDAC, or other selected solid tumors^1–3

A Phase IIa/IIb, open-label, single-arm, multicenter trial of brigimadlin (MDM2-p53 antagonist) for the treatment of patients with locally advanced/metastatic

1. Goyal L, et al. ASCO 2023. Poster TPS4179; 2. NCT05512377. https://clinicaltrials.gov/ct2/show/NCT05512377. Accessed September 2023; 3. Boehringer Ingelheim. Data on file.